Back to search

Netherlands· NL-41e5ab12305f

Teveten Plus, filmomhulde tabletten 600/12,5 mg

A eprosartan und diuretika product containing eprosartanmesilaat + hydrochloorthiazide, registered in Netherlands by Viatris Healthcare B.V.. The same ATC class is registered in 5 of our 19 countries.

ATC C09DA02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedTeveten Plus, filmomhulde tabletten 6…ATCC09DA02REGISTER NO.NL-41e5ab12305fPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Eprosartan und diuretika is registered in 5 of 19 countries.

Countries holding a registration under ATC C09DA02 (eprosartan und diuretika), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 3 of them publish a price we can compare per daily dose

Eprosartan und diuretika · ATC C09DA02

5 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
EPROSARTANMESILAAT + HYDROCHLOORTHIAZIDE
Manufacturer
Viatris Healthcare B.V.
Country
Netherlands (NL)
ATC code
C09DA02
ATC class
Eprosartan und Diuretika
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    25926

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

80 interactions on record for eprosartan und diuretika.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Eprosartan und diuretika · interactions on record

80 records

80 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e4dc1c4f-1831-4b13-89fc-b3dbc9cf58d5
GET /v1/drugs/e4dc1c4f-1831-4b13-89fc-b3dbc9cf58d5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h25926_smpc.pdf",
  "strength": null,
  "atc_label": "Eprosartan And Diuretics",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg25926",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "LACTOSE 1-WATER",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL, GEPREGELATINEERD",
    "POLYVINYLALCOHOL (E 1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "EPROSARTANMESILAAT",
    "HYDROCHLOORTHIAZIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h25926.pdf",
  "authorised_at": "2002/09/05",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "25926",
  "additional_monitoring": "N"
}

See everything about eprosartan und diuretika.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.